Why Abbott’s CEO is excited about Bigfoot Biomedical and diabetes treatment

Share

AbbottJust one week after Abbott (NYSE:ABT) said it inked a deal with Bigfoot Biomedical to develop an automated diabetes management system, CEO Miles White told analysts that he thinks Bigfoot is playing an important role in the strategic change taking place in the space.

“It’s a fairly clever service and approach that I think will create, not just an alternative that makes the management of the disease or management of someone’s insulin easier, but I think the value proposition of it is going to be pretty compelling,” he said yesterday, referencing Bigfoot’s insulin delivery platform.

Get the full story at our sister site, Drug Delivery Business News.

Join us in Southern California this December for DeviceTalks West on 12/11-12/12

textadimage We've attracted a diverse group of thought leaders from some of the Golden State's best medtech companies — including Bigfoot Biomedical, BD, Alphabet's Verily, Integer, Medtronic Neurovascular, Medtronic Diabetes, Smith & Nephew and many more for DeviceTalks West.

Check out our web site for latest news on speakers, agenda and event information.


Get your tickets today! »

Speak Your Mind

*